Harper Health Partners with OpenDNA to Launch AI-Powered Genetic Screening Services
-
Harper Health and OpenDNA have joined forces to provide comprehensive genetic screening services, including TotalRisk+, CardioRisk+, and CancerRisk+ tests that analyze both monogenic and polygenic disease risks.
-
The partnership leverages AI technology to analyze DNA and clinical attributes, with results integrated directly into electronic medical records for streamlined physician workflow and personalized care planning.
-
Patients can access genetic screening through a simple cheek swab, with results available within two weeks, enabling physicians to develop targeted preventive care strategies based on individual risk profiles.
Harper Health, a primary care provider, has announced a strategic collaboration with genetic health solutions company OpenDNA to expand access to advanced genetic screening services. The partnership introduces a comprehensive suite of AI-powered genetic tests designed to identify both monogenic and polygenic risk factors for various health conditions.
The new screening program features three specialized tests: TotalRisk+, CardioRisk+, and CancerRisk+. These tests utilize sophisticated AI technology to analyze patients' DNA in conjunction with clinical attributes, providing detailed insights into individual health risks.
The screening suite offers a multi-faceted approach to genetic risk assessment. TotalRisk+ includes monogenic cancer screening, while CardioRisk+ specifically evaluates risks for cardiovascular conditions, including heart attacks and diabetes. CancerRisk+ focuses on detecting genetic predisposition to multiple cancer types, including prostate, colon, and breast cancer.
A key feature of the partnership is the seamless integration of test results into the electronic medical record (EMR) system. The AI-powered analysis is presented through an interactive user interface, allowing healthcare providers to easily access and interpret genetic data within their existing workflow.
The screening process has been designed with patient convenience in mind. Harper Health patients can undergo genetic testing through a simple cheek swab procedure under physician supervision. Results are typically available within two weeks, after which Harper Health physicians work with patients to interpret findings and develop personalized health management plans.
"By partnering with OpenDNA, we can now offer genetic screening that empowers our patients to take proactive steps towards managing their health and preventing future illness," said Dr. William Harper, CEO and founder of Harper Health. "Understanding individual risk profiles enables our physicians to provide more targeted and effective preventive care recommendations."
The collaboration represents a significant advancement in preventive healthcare, enabling healthcare providers to make informed decisions about lifestyle modifications, treatment alternatives, and preventive care strategies based on individual genetic profiles.

Stay Updated with Our Daily Newsletter
Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.
Related Topics
Reference News
[1]
Harper Health collaborates with OpenDNA to offer monogenic screening
finance.yahoo.com · Feb 18, 2025